AAM
UTHR icon

Aberdeen Asset Management’s United Therapeutics UTHR Stock Holding History

Aberdeen Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$9.3M Sell
71,680
-1,509
-2% -$188K 0.03% 371
2017
Q1 		$9.91M Sell
73,189
-279
-0.4% -$42.3K 0.04% 347
2016
Q4 		$10.5M Sell
73,468
-5,356
-7% -$684K 0.04% 319
2016
Q3 		$9.31M Buy
+78,824
New +$9.47M 0.03% 330

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aberdeen Asset Management's UTHR Position: Q2 2017 in Review

Aberdeen Asset Management reduced its United Therapeutics (UTHR) stake by 2.1% in Q2 2017, selling an estimated $188K and leaving 71,680 shares worth $9.3M. The position accounts for 0.03% of the portfolio, ranked #371.

Aberdeen Asset Management first reported a position in UTHR in Q3 2016 and has held it in 4 quarters since. The position peaked at $10.5M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • Aberdeen Asset Management held 71,680 shares of United Therapeutics worth $9.3M as of Q2 2017.
  • Aberdeen Asset Management sold 1,509 United Therapeutics shares in Q2 2017, an estimated $188K.
  • United Therapeutics made up 0.03% of Aberdeen Asset Management's portfolio in Q2 2017, its #371 holding.
  • Aberdeen Asset Management first reported a position in United Therapeutics in Q3 2016 and has held it in 4 quarters since.
  • Aberdeen Asset Management's United Therapeutics position peaked at $10.5M in Q4 2016.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Aberdeen Asset Management's 13F filing for Q2 2017, filed 10 Aug 2017.